Cd169 (siglec-1) as a robust human cell biomarker of toll-like receptor 9 agonist immunotherapy

HIGHLIGHTS

  • who: Stine Sofie Frank Lende from the Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, Department of Infectious Diseases, Aarhus have published the paper: CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy, in the Journal: (JOURNAL)
  • what: In the recent paper, the authors showed that human STING activation in humanized NOG mice leads to production of human cytokines from human innate immune cells. From the trial , the authors previously reported the plasma levels of IFN-a where the authors observed 12 of 15 trial participants exhibited increases . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?